Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 bioavailability and food effect study in healthy volunteers
NCT05428436Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nerandomilast (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 144 hours, Area Under the Concentration-time Curve of R-BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 144 hours and 2 more. Started Aug 2022; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT05428436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428436.